Julius Knowles

Biography

 Mr. Julius (Jay) Knowles is an investor with Partners Innovation Fund, a $100M fund focused on life science investments in companies emergent from Partners Health Care (the parent organization for Mass General Hospital and Brigham and Womens Hospital, two of the leading academic medical institutions in the US). He was most recently CEO of X-BODY Biosciences, an antibody discovery company, acquired in 2015 by Juno Therapeutics, and before that President of Novalar Pharmaceuticals,a specialty pharmaceutical company that brought a drug from idea stage through the clinic and on to the market. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents the fund at the boards of Editas, LTI, Quartet, RaNA and Raze, and is on the board of Aurigene as an independent director.  

Research Interest

 Genome